drugset / Trial / NCT03540420
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
Phase 2
Active not recruiting
212 enrolled
Norwegian University of Science and Technology
Aalborg University Hospital · collabAlesund Hospital · collabAmphia Hospital · collabCantonal Hospital of St. Gallen · collabEnte Ospedaliero Cantonale, Bellinzona · collabErasmus Medical Center · collabFreiburger Spital · collabGävle Hospital · collabHaukeland University Hospital · collabHelse Fonna · collabHelse Nord-Trøndelag HF · collabHelse Stavanger HF · collabInsel Gruppe AG, University Hospital Bern · collabIsala · collabKantonsspital Graubünden · collabKantonsspital Olten · collabKantonsspital Winterthur KSW · collabKarolinska University Hospital · collabKlinik Hirslanden, Zurich · collabKristiansund Hospital · collabMedisch Spectrum Twente · collabMolde Hospital · collabNational Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · collabNordlandssykehuset HF · collabOdense University Hospital · collabOslo University Hospital · collabRigshospitalet, Denmark · collabRijnstate Hospital · collabSahlgrenska University Hospital · collabSkane University Hospital · collabSorlandet Hospital HF · collabSpital STS AG · collabSt. Antonius Hospital · collabSt. Olavs Hospital · collabThe Netherlands Cancer Institute · collabUllevaal University Hospital · collabUniversity Hospital of North Norway · collabUniversity Hospital, Akershus · collabUniversity Hospital, Basel, Switzerland · collabUniversity Hospital, Linkoeping · collabVestre Viken Hospital Trust · collabVolda Hospital · collabZuyderland Medisch Centrum · collabÔrebro University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.
Timeline
- Start
- 2018-07-31
- Primary completion
- 2024-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |